therapy

Contemporary Care Introduces TMS Therapy to Naples, Florida

Image by Contemporary Care NAPLES, Fla., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Contemporary Care today announced the availability of Transcranial…

2 months ago

FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase…

2 months ago

Cirrus Therapeutics Raises $11 M Seed Financing to Advance Novel Ocular Gene Therapy to Reverse Underlying Age-Related Cause of Dry AMD

October 02, 2025 10:00 ET  | Source: Cirrus Therapeutics, Inc. Cirrus’ lead program is a novel AAV gene therapy designed…

2 months ago

Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025

September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with…

2 months ago

Advanced CAR-T Cell Therapy in a Young Engineer Battling High-Risk Pre-B Acute Lymphoblastic Leukemia

KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for cancer care in Eastern India, doctors at Apollo…

2 months ago

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most…

3 months ago

Booking Health Expands Access to Dendritic Cell Therapy After Study Confirms Survival Benefit in Glioblastoma Patients

September 09, 2025 13:19 ET  | Source: Booking Health Langenfeld, Germany, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Booking Health, a…

3 months ago

Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been approved based on an objective…

3 months ago

New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or…

3 months ago

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…

4 months ago